Wendell David Associates Inc. Sells 200 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Wendell David Associates Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,440 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. Wendell David Associates Inc.’s holdings in Gilead Sciences were worth $1,506,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $35,000. Whipplewood Advisors LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $35,000. Synergy Investment Management LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $41,000. Institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer now directly owns 620,268 shares in the company, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,000 shares of company stock valued at $4,630,310. Company insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on GILD shares. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Wells Fargo & Company upped their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Oppenheimer dropped their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, April 25th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $110.55.

Gilead Sciences Stock Up 0.8%

Shares of GILD opened at $110.83 on Tuesday. The business’s fifty day moving average price is $105.82 and its two-hundred day moving average price is $102.45. The firm has a market capitalization of $137.86 billion, a price-to-earnings ratio of 299.54, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences, Inc. has a 52 week low of $62.69 and a 52 week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business earned ($1.32) earnings per share. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.85%. Gilead Sciences’s payout ratio is presently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.